bleximenib + venetoclax

Bleximenib + venetoclax is an investigational combination therapy currently under evaluation as part of a multi-drug regimen for acute myeloid leukemia (AML), particularly subtypes harboring *KMT2A* rearrangements or *NPM1* mutations in patients who are ineligible for intensive chemotherapy or have relapsed/refractory disease. - Bleximenib (JNJ-75276617) is a selective small molecule menin inhibitor that blocks the interaction between menin and KMT2A (histone-lysine N-methyltransferase 2A), disrupting leukemogenic transcriptional programs. - Venetoclax is a small molecule inhibitor of BCL-2, promoting apoptosis in leukemic cells. - The combination (often also with azacitidine, a hypomethylating agent) has demonstrated promising clinical activity and a favorable safety profile in Phase 1b and currently in Phase 3 clinical trials for AML patients with relevant molecular features[1][2][3][4][5]. - Developed and sponsored by Johnson & Johnson for bleximenib and AbbVie for venetoclax.

Other names

JNJ-75276617 + venetoclax